Cancer Genetics — FY2016 Earnings Presentation
17 slides from Cancer Genetics's earnings presentation, Mar 23, 2017
Slide 1: Q4 & Full Year 2016 Earnings Report & Company Updates
CANCER GENETICS INCORPORATED Empowering Personalized Cancer Treatment Q4 & Full Year 2016 Earnings Report & Company Updates CGIX Thursday — March 23, 2017 | 09:00am Eastern | CEO: Panna Sharma NASDAg Listeo
Slide 2: Forward-Looking Statements
Gi Forward-Looking Statements These slides may contain forward-looking statements within the meaning of - priate Secuitioe Litigation Bsipm Act of 1995. All statements pertaining to future financial and/or operating results, research, technology, clinical development and potential opportunities for
Slide 3: Everything We Do Is Focused on 1 Key Idea
—— ee EVERYTHING WE DOISFOCUSED ON 1 KEY IDEA... ...DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES IN PRECISION MEDICINE FOR ONCOLOGY DIAGNOSTICS.
Slide 4: Investor Highlights: Cancer Genetics Addresses Key Trends in Oncology
Investor Highlights: Cancer Genetics Addresses G Key Trends in Oncology from Bench to Bedside Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly ic M&A Strategic 3 TRANSFORMATIVE ACQUISITIONS of 10 TOP BIOPHARMA *488 * REVENUE INCREASE (2013-16)
Slide 5: Revenue & Growth Highlights
Gi Revenue & Growth Highlights 46 Quarter Total Revenue Year End Total Revenue $27.0M Numbers in $ millions Numbers in $ mi 2013 2014 2015 2016 Q4 2013 Q42014 Q42015 4 2016 1 1 1 1 1 1 1 1 Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 & FY 2016 Eamings Call
Slide 6: Operational Integration and Streamlining
Gi Operational Integration and Streamlining REVENUE & OPERATING EXPENSES + Operating expenses were reduced b: $1.5 million from Q4 of 2015 thru Q4 of 2016 based on streamlining operations across sites, and transforming our clinical go-to-market model. « We expect ongoing improvements in the top line
Slide 7: Revenues By Category
Gi Revenues By Category 515.3M [ff] BIOPHARMA SERVICES * CGI is now supporting over 125 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 36 for immuno-oncology indications $10.7M |_| CLINICAL SERVICES Full Year’ 2016 + 204% increase in clinical test volume over 2015 du
Slide 8: Full Year 2016 Financial Highlights
Gi Full Year 2016 Financial Highlights = FY 2016 revenues were 527.0 million, a 50” increase over FY 2015 revenues of $18.0 million. + Revenue from Biopharma Services grew 32”; Clinical Services grew 88”; and Discovery Services grew 31” year-over-year. = Total operating expenses were $26.7 million,
Slide 9: Q4 2016 Financial Highlights
Gi Q4 2016 Financial Highlights = Q4 2016 revenues were $7.2 million, a 32” increase over Q4 2015 revenues of §5.5 million. » Revenue from Biopharma Services grew 34”; Clinical Services increased by 25”; and Discovery Services grew 102” year-over-year during the fourth quarter. = Total operating exp
Slide 10: Debt Refinancing
Gi Debt Refinancing = Closed a $12 million debt refinancing with Silicon Valley Bank and Partners for Growth, allowing the Company to access ~$7.6 million in additional capital net of paying off $4.4 million term loan with Silicon Valley Bank. = The new $12 million debt facilities will be used in pa
Slide 11: Q4 2016 Biopharma Highlights
Gi Q4 2016 Biopharma Highlights « Working with 9 out of the 10 top biopharma companies in 2016. » Revenue from biopharma partners and customers increased by 32% to $15.3 million in 2016 as compared to $11.6 million during 2015. = For the fourth quarter of 2016, bi revenues i 34% to $4 million up fro
Slide 12: 2016 Clinical & Discovery Highlights
Gi 2016 Clinical & Discovery Highlights = Clinical services revenue growth was 88% for the full year of 2016 over 2015, from $5.7 million to $10.7 million. = For the fourth quarter of 2016, clinical services revenue increased 25% over the same period in 2015, from $2.4 million to $3 million. This gr
Slide 13: Summary Statement of Operations
Gi Summary Statement of Operations Income Statement Items ¢s in mousanes) Q4 2016 Q4 2015 Full Year 2016 Full Year 2015 Revenue $7,230 $5,484 $27,049 $16,040, Gross Profit $2,958 $728 $9,945 $3,942 Gross Margin (%) 41% 13% 37% 22% Research & Development (R&D) $1,161 $1,148 $5,967 $5,483 Sales & Mark
Slide 14: 2016 Biopharma Highlights: Additional Key Metrics
2016 Biopharma Highlights: Additional Key Metrics Number of i y ite Proj Qt 2016 v. 4 2016 Qt 2046 v. Q4 2016 Q1 2016 v. Q4 2016 130 ne 20 fn 19 110 103 18 18 90 10 10 70 5 3 ‘ 4 50 12016 24 2016 a1 2016 24 2016 a1 2016 4 2016 Realized a 35% increase in number of biopharma projects managed from 103
Slide 15: Q4 2016 Biopharma Highlights: Case Study
Q4 2016 Biopharma Highlights Case Study Gi trial support partner for 2 novel i In Q4 2016, CGI commenced services as a biomarker Siseavnty, assay development, and clinical gy industry-leading major biotech company. Program 1 Program 2 + 41HC markers, including PD-L1* + 2 ISH markers* + 2 Solid Tumor
Slide 16: 2017 Upcoming Milestones
2017 Upcoming Milestones 1st Half 2017 2nd Half 2017 Launch of: Launch of: + Hereditary Cancer Testing Panels + Liquid Biopsy for Lung Cancer Profiling + Al engine to improve clinical trial matching + Liquid Biopsy for Kidney Cancer + Development of Network of Genetic Counselors + Expand Hereditary
Slide 17: CGI Headquarters and Office Locations
CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 RALEIGH, NC LOS ANGELES, CA 1640 Marengo Street Fourth Floor Los Angeles, CA 90033 Phone: +1 323-224-3900 #3-1-135/